Ve­ra Ther­a­peu­tics sprints to PhI­II with treat­ment for rare kid­ney dis­ease

Ve­ra Ther­a­peu­tics un­veiled top-line mid-stage da­ta on Tues­day sug­gest­ing its fu­sion pro­tein drug at­aci­cept suc­cess­ful­ly im­proved kid­ney func­tion in pa­tients with a rare au­toim­mune dis­ease. Two low­er dos­es, how­ev­er, failed to move the nee­dle on their own.

A pooled group of im­munoglob­u­lin A nephropa­thy (IgAN) pa­tients tak­ing ei­ther a 75 mg or 150 mg dose of at­aci­cept saw a 31% mean re­duc­tion from base­line in pro­tein­uria — a mea­sure­ment of pro­tein lev­els in the urine — com­pared to 7% in the place­bo group (p=0.037) at 24 weeks, Ve­ra an­nounced on Tues­day, meet­ing the pri­ma­ry end­point. While the 25 mg and 75 mg dose groups failed to meet sta­tis­ti­cal sig­nif­i­cance on their own, the 150 mg group showed a 33% re­duc­tion (p=0.047), and that’s the dose that re­searchers plan on tak­ing in­to Phase III.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER